Diabetic macular edema. unspecified diabetic retinopathy with macular edema
Conditions
Interventions
Intervention 1: Control group: For this group, in sterile conditions, 3 intravitreal injections of bevacizumab with a dose of 1.25 mg will be performed at one-month intervals. In this group, patients
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Diabetic patients over 18 years old Macular edema involving the center. BCVA between 20/400-40/20 Central macular thickness greater than or equal to 300 µm Requires 3 IVB injections in the next 12 weeks Retinal clarity, pupillary dilation for OCT, and necessary cooperation for proper fundus photography
Exclusion criteria
Exclusion criteria:
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Improve visual acuity. Timepoint: Before the study and one month after the third injection of bevacizumab. Method of measurement: Optometry. | — |
Primary
| Measure | Time frame |
|---|---|
| Decrease thickness of the central part of the macula. Timepoint: At the beginning of the study and one month after the third injection of bevacizumab. Method of measurement: Oct device (Optical coherence tomography). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahdi noori
Shahid Beheshti University of Medical Sciences
Outcome results
None listed